🇺🇸 recombinant human hyaluronidase in United States

17 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pneumonia — 3 reports (17.65%)
  2. Osteomyelitis — 2 reports (11.76%)
  3. Paraesthesia — 2 reports (11.76%)
  4. Staphylococcal Infection — 2 reports (11.76%)
  5. Staphylococcus Test Positive — 2 reports (11.76%)
  6. Wound Infection Staphylococcal — 2 reports (11.76%)
  7. Acute Kidney Injury — 1 report (5.88%)
  8. Ascites — 1 report (5.88%)
  9. Colitis Ulcerative — 1 report (5.88%)
  10. Completed Suicide — 1 report (5.88%)

Source database →

recombinant human hyaluronidase in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is recombinant human hyaluronidase approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for recombinant human hyaluronidase in United States?

Halozyme Therapeutics is the originator. The local marketing authorisation holder may differ — check the official source linked above.